This single-center retrospective observational cohort study aims to evaluate the clinical, hemodynamic, and laboratory effects of adjunctive hemoadsorption therapy in critically ill adult patients treated in the Intensive Care Unit of Flór Ferenc Hospital, Hungary, between January 1, 2020, and May 31, 2026. Patients who received CytoSorb or Efferon LPS hemoadsorption therapy will be included.
The study will assess changes in vasopressor requirements, hemodynamic parameters, inflammatory biomarkers, liver function tests, tissue perfusion markers, and oxygenation following hemoadsorption treatment. Clinical outcomes, including intensive care unit length of stay, ICU mortality, and 28-day and 90-day mortality, will also be evaluated. Data will be collected retrospectively from anonymized medical records, and no study-related interventions will be performed.
>18 years;
CytoSorb or Efferon LPS hemoadsorption treatment,
with available relevant pre- and post-treatment clinical and laboratory data
age under 18 years
missing key demographic or outcome data;
unknown treatment type or timing;
data unavailable for legal or ethical reasons.